Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) Book Value per Share : $0.00 (As of Nov. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Cannabis Bioscience International Holdings Book Value per Share?

Cannabis Bioscience International Holdings's book value per share for the quarter that ended in Nov. 2023 was $0.00.

During the past 12 months, Cannabis Bioscience International Holdings's average Book Value Per Share Growth Rate was -100.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 511.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Cannabis Bioscience International Holdings was 511.80% per year. The lowest was 511.80% per year. And the median was 511.80% per year.

Cannabis Bioscience International Holdings's current price is $0.0006. Its book value per share for the quarter that ended in Nov. 2023 was $0.00. Hence, today's PB Ratio of Cannabis Bioscience International Holdings is 0.00.

During the past 5 years, the highest P/B Ratio of Cannabis Bioscience International Holdings was 0.02. The lowest was 0.01. And the median was 0.01.

Cannabis Bioscience International Holdings Book Value per Share Historical Data

The historical data trend for Cannabis Bioscience International Holdings's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannabis Bioscience International Holdings Book Value per Share Chart

Cannabis Bioscience International Holdings Annual Data

Trend

Dec06

Dec07

May09

May10

May11

Book Value per Share

-0.09

0.02

13.65

3.75

4.81

Cannabis Bioscience International Holdings Semi-Annual Data
	Dec06	Jun07	Dec07	Jun08	May09	Nov09	May10	Nov10	May11	Nov11	Nov22	Nov23
Book Value per Share	Get a 7-Day Free Trial							4.55	4.81	4.94	-	-

Competitive Comparison of Cannabis Bioscience International Holdings's Book Value per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Bioscience International Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannabis Bioscience International Holdings's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Bioscience International Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where Cannabis Bioscience International Holdings's PB Ratio falls into.

Cannabis Bioscience International Holdings Book Value per Share Calculation

Cannabis Bioscience International Holdings's Book Value Per Share for the fiscal year that ended in May. 2011 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(62.17	-	0.00)	/	12.93
	=	4.81

Cannabis Bioscience International Holdings's Book Value Per Share for the quarter that ended in Nov. 2023 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-0.84	-	0.00)	/	10,331.70
	=	-0.00

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Cannabis Bioscience International Holdings (OTCPK:CBIH) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Cannabis Bioscience International Holdings Book Value per Share Related Terms

Thank you for viewing the detailed overview of Cannabis Bioscience International Holdings's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannabis Bioscience International Holdings Inc (OTCPK:CBIH) » Definitions » Book Value per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

6201 Bonhomme Road, Suite 466S, Houston, TX, USA, 77036

Website

https://www.cbih.net

Cannabis Bioscience International Holdings Inc is engaged in providing educational systems relating to cannabis and services in therapeutic areas. of clinical trials and services relating to sleep disorders through its sleep center in Houston, Texas. The Company generates revenue from multiple streams, namely, clinical trials, consulting fees, video courses, seminars, royalties, and merchandise sales. The company generates the majority of its revenue from clinical trials.